Release Date: May 14, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Codexis Inc (NASDAQ:CDXS) maintained a strong financial position, ensuring a runway to cash flow positivity by the end of 2026. The company has made meaningful progress across both core businesses, setting up for a substantial revenue ramp in the second half of the year. Product gross margin improved to 55% in Q1 2025 from 49% in Q1 2024, driven by a shift to more profitable products. Codexis Inc (NASDAQ:CDXS) has secured new customers, particularly within the mid-tier pharma segment, positioning for steady growth. The company is leveraging machine learning capabilities to improve enzyme selection and process efficiency, enhancing its competitive edge.

Negative Points

Total revenue for Q1 2025 was $7.5 million, a significant decrease from $17.1 million in Q1 2024, highlighting revenue volatility. The net loss for Q1 2025 increased to $20.7 million compared to $11.5 million in Q1 2024. Revenue can be impacted by the unpredictability of large orders, as seen with a delayed $2.5 million order affecting Q1 results. Research and development expenses increased to $12.9 million in Q1 2025 from $11.2 million in Q1 2024, driven by higher salaries and lab costs. The company faces challenges in getting small and large SIRNA drug innovators to adopt its technology early, as they are either cash-strapped or focused on future demand.

Q & A Highlights

Warning! GuruFocus has detected 5 Warning Signs with CDXS.

Q: How do you plan to engage small and large SIRNA drug innovators to adopt your technology earlier? A: Unidentified_3 (CEO): The key is demonstrating the efficiency and scalability of our technology. CDMOs are easier to engage due to their existing customer relationships and forward planning. For drug innovators, we need to show that our process is faster, cheaper, and can be stood up quickly. It's about execution now, not invention.

Q: Can you provide more details on the expected revenue ramp in the second half of the year? A: Unidentified_5 (CFO): The revenue ramp is expected due to new contracts with our ecosynthesis platform. The growth will be more pronounced in the latter half of the year as these deals are finalized.

Q: What are the assumptions behind the 2026 cash flow positivity guidance, and how could a GMP facility investment affect this? A: Unidentified_3 (CEO): The guidance is based on organic pipeline growth and does not include a GMP facility. The facility would accelerate revenue growth but requires external funding. We plan to finance it in stages, aligning with order flow to ensure demand before building.

Story Continues

Q: Can you elaborate on the orders for the ligate from large pharma and other innovators? A: Unidentified_3 (CEO): We expect these to become repeat customers. Orders typically start small and grow as products move from phase 2 to phase 3 trials. The timeline to peak sales is shorter than traditional pharma, around 3 to 5 years.

Q: How are you integrating machine learning capabilities, and what impact could this have on operations? A: Unidentified_3 (CEO): We've applied machine learning to optimize enzyme selection for ligation, significantly improving efficiency. This technology is being used successfully by our partners, and we plan to expand its application to other areas, enhancing our core technology and manufacturing processes.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments